ライフサイエンスコーパス: ACEI

1 ACEI suppresses the development of MCT-induced PAH in ra

2 ACEI therapy was associated with a striking increase in

3 ACEI/ARB administration was associated with a significan

4 ACEI/ARB therapy had a significant negative effect on th

5 ACEI/ARB use was defined as prescription fillings 6 mont

6 ACEI/ARB use was independently associated with acute kid

7 ACEI/ARB use was independently associated with the follo

8 >=1 in/outpatient HF encounter, and (3) >=1 ACEI or ARB fill, all within 1-year preindex.

9 tic agents alone to three treatment arms: 1) ACEI therapy alone; 2) ACEI+BB; and 3) ACEI+BB+AldA.

10 ee treatment arms: 1) ACEI therapy alone; 2) ACEI+BB; and 3) ACEI+BB+AldA.

11 ACEI and increased prednisone dose (n = 2), ACEI or ARB only (n = 2).

12 s: 1) ACEI therapy alone; 2) ACEI+BB; and 3) ACEI+BB+AldA.

13 ror [SE]: 2.7%), statin in 33.1% (SE: 2.4%), ACEI/ARB in 28.4% (SE: 2.0%), and cilostazol in 4.7% (SE

14 ia; 12 were treated with: rituximab (n = 8), ACEI and increased prednisone dose (n = 2), ACEI or ARB

15 3.9), statins (OR: 2.6; 95% CI: 1.8 to 3.9), ACEI/ARB (OR: 2.6; 95% CI: 1.8 to 3.9), and smoking cess

16 , adjusted OR: 8.22 (95% CI: 6.20 to 10.90); ACEI/ARBs, adjusted OR: 5.80 (95% CI: 2.56 to 13.16); p

17 ssess the factors associated with filling an ACEI prescription in the 30 days postdischarge and the p

18 for sacubitril/valsartan and if none, for an ACEI or ARB.

19 statin (7.1% vs. 4.8%, p < 0.0001) or for an ACEI/ARB (29.1% vs. 22.4%, p < 0.0001), but similar prop

20 sacubitril/valsartan versus maintained on an ACEI or ARB.

21 d ejection fraction (HFrEF), who tolerate an ACEI (angiotensin-converting enzyme inhibitor) or ARB (a

22 % started therapy with a statin, 11% with an ACEI/ARB, and 5% with both.

23 The cost-savings in the ACEI and ACEI+BB cohorts compared to that with diuretics alone we

24 Treatment with ACEI and ACEI+BB strictly dominated treatment with diuretics only

25 High-dose AT1RA and ACEI markedly decreased progression of sclerosis, with -

26 io (ICER) of ACEI+BB+AldA versus ACEI+BB and ACEI+BB versus ACEI was <$1,500 per quality-adjusted lif

27 Combined BB and ACEI/ARB use was associated with the lowest incidence of

28 Combined BB and ACEI/ARB was associated with the lowest incidence of all

29 managed with revascularization, both BB and ACEI/ARB were associated with a lower incidence of 12-mo

30 In addition, GABA and ACEI activity of LSF increased in a time-dependent manne

31 on is associated with lower serum lipids and ACEI in patients after TX.

32 detected between baseline urine protein and ACEI therapy (P = 0.003).

33 s, goal doses of beta-blockers, statins, and ACEI/ARBs were achieved in only 12%, 26%, and 32% of eli

34 n between sacubitril/valsartan switchers and ACEI or ARB maintainers.

35 kers, HR, 0.61 and 95% CI, 0.57 to 0.65; and ACEIs among heart failure patients, HR, 0.75 and 95% CI,

36 nvestigated the effects of AT(1) antagonism, ACEI, and their combination in a well-characterized ovin

37 ose AT1RA, high-dose ACEI, and varying AT1RA+ACEI combinations.

38 action, addition of eplerenone to background ACEI or ARB therapy attenuates the progressive decline i

39 Adjusting for the use of statins, BBs, ACEIs/ARBs, and antiplatelet drugs after discharge compl

40 orded filled prescriptions for statins, BBs, ACEIs/ARBs, or antiplatelet agents within 30 days after

41 a dose-dependent inverse association between ACEI use and the risk for developing ALS.

42 The association between ACEI/ARB treatment and outcomes (mortality, myocardial i

43 Most head-to-head comparisons between ACEI and ARB have yielded comparable CV protective effec

44 dose-response relationship was found between ACEI dose and HCT.

45 terone system inhibition with dual blockade, ACEI and angiotensin receptor antagonists, on renal volu

46 receiving target doses of MRA, beta-blocker, ACEI/ARB, and ARNI therapy, respectively.

47 me inhibitors/angiotensin receptor blockers (ACEI/ARB) in acute myocardial infarction (AMI) were larg

48 re are ample data to support a role for both ACEI and ARB to prevent the progression from microalbumi

49 e exception occurred in patients taking both ACEI and BB as co-treatment, in whom the decrease in LVI

50 ive ACEI than were nondiabetic patients, but ACEI use was quite low even among diabetic patients with

51 expression of p21 and eNOS was modulated by ACEI treatment in a rat model.

52 we assessed the association between chronic ACEI/ARB use and the occurrence of kidney, lung, heart,

53 of nondialysis-dependent patients with CKD, ACEI/ARB administration was associated with greater surv

54 bitor (ACEI) who were randomized to continue ACEI until the morning of surgery (ACEI group, n=19) or

55 , 86.5% used ACEI/ARBs vs 85.4% of controls; ACEI/ARB use compared with other antihypertensive drugs

56 2; P = .001) for the group with a cumulative ACEI use of greater than 449.5 cDDD.

57 l actions than ACE inhibition plus diuretic (ACEI+D) in congestive heart failure.

58 erimental congestive heart failure than does ACEI+D.

59 I (sACEI; ramipril 10 mg/d, n=14), high-dose ACEI (hACEI; ramipril 20 mg/d, n=8), AT(1) blockade (los

60 Compared with low dose, high-dose ACEI or ARBs decreased all-cause mortality modestly (rel

61 treatment (CONT), high-dose AT1RA, high-dose ACEI, and varying AT1RA+ACEI combinations.

62 ecreased by all treatments, except high-dose ACEI, which showed persistent proteinuria.

63 s: no therapy (control, n=12), standard-dose ACEI (sACEI; ramipril 10 mg/d, n=14), high-dose ACEI (hA

64 in assay and DNA laddering before and during ACEI therapy.

65 th risk is continuous but is lost with early ACEI therapy.

66 Beyond a simple antihypertensive effect, ACEIs have been shown to reduce the rates of myocardial

67 ted that valsartan therapy taken with either ACEI or BB reversed LV remodeling.

68 egistered randomized trials plan to evaluate ACEIs and ARBs for treatment of COVID-19.

69 mposite outcome of AKI and mortality favored ACEI/ARB treatment.

70 ockers only, 0.98 (95% CI: 0.91 to 1.07) for ACEI/ARBs and statins only, 1.17 (95% CI: 1.10 to 1.25)

71 ere 6% for MRA, 10% for beta-blocker, 7% for ACEI/ARB, and 10% for ARNI; corresponding proportions wi

72 ssion ratios than patients receiving PCI for ACEI/ARBs (69.4% vs. 77.8%, p < 0.0001), beta-blockers (

73 Except for ACEIs among patients without heart failure, consistent u

74 Patients with a discharge order for ACEIs were more likely to fill a prescription within 30

75 st, for patients with no discharge order for ACEIs, only 12.7%/12.0% (depressed EF/total cohort) had

76 g approved drugs that target the generation (ACEIs) and actions (ARBs) of Ang II.

77 We also discuss why and how ACEIs and ARBs provide cardiovascular, renal and also pu

78 incidence of major cardiovascular events in ACEI-treated recipients.

79 e Telmisartan Randomized Assessment Study in ACEI Intolerant Subjects With Cardiovascular Disease (TR

80 ACE inhibition (ACEI) attenuates post-myocardial infarction (MI) LV remo

81 rolled clinical trials (RCT), ACE inhibitor (ACEI) and angiotensin receptor blocker (ARB) therapy hav

82 ACE inhibitor (ACEI) may have beneficial effects in treating PAH, but i

83 vity in 31 patients taking an ACE inhibitor (ACEI) who were randomized to continue ACEI until the mor

84 her angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) should be u

85 ing angiotensin-converting enzyme inhibitor (ACEI) and/or beta-blocker (BB) were randomized into vals

86 or angiotensin-converting enzyme inhibitor (ACEI) has demonstrated particular promise in patients wi

87 ith angiotensin-converting enzyme inhibitor (ACEI) monotherapy.

88 er, angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB), and diur

89 ing angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor antagonist (ARB) therapy,

90 of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) influences d

91 ved angiotensin-converting enzyme inhibitor (ACEI) therapy at the end of the trial and were followed

92 rom angiotensin-converting enzyme inhibitor (ACEI) therapy when they are at low risk for disease prog

93 ent angiotensin-converting enzyme inhibitor (ACEI) use after heart failure (HF) hospitalization.

94 r angiotensin I converting enzyme inhibitor (ACEI) were investigated.

95 of angiotensin-converting enzyme inhibitor (ACEI), beta-blocker (BB), and aldosterone antagonist (Al

96 an angiotensin-converting enzyme inhibitor (ACEI).

97 of angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB), angiotensin

98 een angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) use and mortali

99 s, angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB).

100 en angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) doses on o

101 Angiotensin converting enzyme inhibitors (ACEI) are efficacious in lowering the hematocrit of pati

102 Angiotensin-converting enzyme inhibitors (ACEI) are the treatment of choice in PTE, but their mech

103 Angiotensin II converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) presumab

104 of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs) does no

105 s, angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) are general

106 Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) initiated a

107 er angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB).

108 le angiotensin-converting enzyme inhibitors (ACEI) to downregulate the renin-angiotensin system.

109 ng angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), beta-blocker

110 on angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARBs), beta-blocke

111 of angiotensin converting enzyme inhibitors (ACEI).

112 nd angiotensin-converting enzyme inhibitors (ACEI)/angiotensin II receptor blockers (ARBs) at dischar

113 of angiotensin-converting enzyme inhibitors (ACEI, P < .05), and to have a lower volumetric remodelin

114 ACE inhibitors (ACEIs) and angiotensin II type 1 (AT(1)) receptor blocke

115 19 cohorts has revealed that ACE inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) may be be

116 ly angiotensin-converting enzyme inhibitors (ACEIs) (beta = -1.66; 95% CI, -2.57 to -0.75; P < 0.001)

117 of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs) in coron

118 th angiotensin-converting enzyme inhibitors (ACEIs) improves MPR in patients with hypertension by pot

119 of angiotensin-converting enzyme inhibitors (ACEIs) in coronary artery bypass graft surgery has been

120 of angiotensin-converting enzyme inhibitors (ACEIs) in patients with coronary heart disease and prese

121 of angiotensin-converting enzyme inhibitors (ACEIs) in those with and without heart failure.

122 Angiotensin-converting enzyme inhibitors (ACEIs) may retard the development of CAV but have not be

123 of angiotensin-converting enzyme inhibitors (ACEIs) on hematocrit values in those with heart failure,

124 Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) are widel

125 of angiotensin-converting enzyme inhibitors (ACEIs) potentially decreased amyotrophic lateral scleros

126 ), angiotensin-converting enzyme inhibitors (ACEIs), and angiotensin-II receptor blockers (ARBs) have

127 to angiotensin-converting enzyme inhibitors (ACEIs), calcium antagonists (CCBs) and alpha-blockers in

128 to angiotensin-converting enzyme inhibitors (ACEIs), single-nucleotide polymorphisms (SNPs) in the an

129 to angiotensin-converting enzyme inhibitors (ACEIs).

130 of angiotensin-converting enzyme inhibitors (ACEIs).

131 at angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) may make pat

132 s, angiotensin-converting enzyme inhibitors [ACEIs] or angiotensin receptor blockers [ARBs], and cilo

133 n (angiotensin-converting enzyme inhibitors [ACEIs], angiotensin receptor blockers [ARBs], and beta-b

134 angiotensin I-converting enzyme inhibitory (ACEI) activities than SSF.

135 nd angiotensin converting enzyme inhibitory (ACEI) activity (>90%).

136 ened awareness of the phenomenon of isolated ACEI-associated visceral angioedema is necessary given t

137 MCT(+)/ACEI(+) rats showed a preserved right ventricular morpho

138 ther group did not receive enalapril (MCT(+)/ACEI(-) rats).

139 21 and eNOS expression in the lung in MCT(+)/ACEI(-) rats, whereas their expression was preserved wit

140 owed right ventricular hypertrophy in MCT(+)/ACEI(-) rats.

141 ncomitantly with enalapril treatment (MCT(+)/ACEI(+) rats), and the other group did not receive enala

142 e of 2 or more antihypertensive medications, ACEI, and diuretics were associated with a loss of struc

143 For NDTI, ACEI use in CHF increased from 24% in 1990 to 36% in 199

144 l, 923 (21.8%); addition, 343 (8.1%); and no ACEI, 2043 (48.4%).

145 Continuous treatment with ACEI versus no ACEI was associated with substantive reductions of risk

146 CEI de novo postoperatively compared with no ACEI therapy was also associated with a significant redu

147 o discontinue it 48 hours before surgery (No-ACEI group, n=12).

148 line to POD1 (P=0.009) were higher in the No-ACEI group (from 17.0+/-5.0 to 48.7+/-8.8 ng/mL) versus

149 tly greater in the ACEI group than in the No-ACEI group (P=0.030).

150 subgroup originally randomly assigned to non-ACEI therapy.

151 Furthermore, continuation of ACEI or de novo ACEI therapy early after cardiac surgery is associated w

152 There were 895 users (20.0%) of ACEI/ARBs and 3585 nonusers (80.0%).

153 The 3-year mortality was 19.8% (17.4% of ACEI/ARB users and 25.4% of nonusers).

154 at biopsy in 62% of AT1RA-treated and 57% of ACEI-treated rats.

155 eath or severe COVID-19 occurred in 31.9% of ACEI/ARB users vs 14.2% of nonusers by 30 days (adjusted

156 Addition of ACEI de novo postoperatively compared with no ACEI thera

157 sufficient evidence about the association of ACEI or ARBs with mortality in patients with CKD.

158 We examined the association of ACEI/ARB administration with all-cause mortality in pati

159 The association of ACEI/ARB treatment with lower risk of mortality was pres

160 was no variation in the degree of benefit of ACEI therapy (P = 0.93 for the treatment x risk interact

161 However, there was no benefit of ACEI therapy among patients with proteinuria <500 mg/d,

162 We report the first known case of ACEI-associated visceral angioedema occurring in a liver

163 a-analysis suggested that the combination of ACEI+BB+MRA was associated with a 56% reduction in morta

164 Furthermore, continuation of ACEI or de novo ACEI therapy early after cardiac surgery

165 e findings do not support discontinuation of ACEI/ARB medications that are clinically indicated in th

166 udy was to investigate the effect of dose of ACEI and ARBs on outcomes and drug discontinuation in pa

167 The daily dose of ACEI/ARB was independently associated with altered kidne

168 , compared with lower doses, higher doses of ACEI and ARB significantly though modestly improved the

169 ontrolled trials that compared high doses of ACEI or ARB against low doses among patients with HF wit

170 simultaneously treated with target doses of ACEI/ARB/ARNI, beta-blocker, and MRA.

171 enylyl cyclase (AC) by testing the effect of ACEI and ARB in mice with juxtaglomerular cell-specific

172 ase progression, but the treatment effect of ACEI does not vary across risk strata.

173 Although the CV protective effect of ACEI in high-risk populations is widely appreciated, whe

174 t, reversed the basal vasodilatory effect of ACEI in the pulmonary vasculature.

175 In this report, the effect of ACEI on CD34+ erythroid precursor apoptosis was studied,

176 have demonstrated a CV protective effect of ACEI when compared with other active agents in patients

177 cremental cost-effectiveness ratio (ICER) of ACEI+BB+AldA versus ACEI+BB and ACEI+BB versus ACEI was

178 In particular, the low likelihood of ACEI/ARB after coronary artery bypass grafting surgery o

179 with time after TX, hypertension, nonuse of ACEI, donor age, and changes in total cholesterol and tr

180 Postoperatively, the pattern of ACEI use yielded 4 groups: continuation, 915 (21.7%); wi

181 ysis was used to calculate the propensity of ACEI/ARB initiation in 141,413 U.S. veterans with nondia

182 omes were anticipated to be equal to that of ACEI.

183 On the other hand, continuous treatment of ACEI versus withdrawal of ACEI was associated with decre

184 ify randomized, placebo-controlled trials of ACEI use in patients with CAD and preserved LV systolic

185 ed to examine the association between use of ACEI/ARBs vs other antihypertensive drugs and the incide

186 Prior use of ACEI/ARBs was not significantly associated with COVID-19

187 Our study suggests that withdrawal of ACEI treatment after coronary artery bypass graft surger

188 nuous treatment of ACEI versus withdrawal of ACEI was associated with decreased risk of the composite

189 for example, inhalational administration of ACEIs/ARBs (to deliver drugs directly to the lungs) and

190 flicting evidence concerning the benefits of ACEIs in patients with coronary artery disease (CAD) and

191 -analysis shows a modest favorable effect of ACEIs on the outcome of patients with CAD and preserved

192 Use of ACEIs exhibited a dose-dependent inverse association wit

193 Use of ACEIs was analyzed using a conditional logistic regressi

194 Use of ACEIs was associated with a decrease in cardiovascular m

195 d discharge and continuous follow-up data on ACEI/ARB use among AMI survivors (2006 to 2009) included

196 Patients on ACEI had significantly lower HCT (P = 0.005) compared wi

197 st to control subjects, patients with PTE on ACEI showed a significant decrease in IGF-1 levels and a

198 essures to a greater level than OMA alone or ACEI+D.

199 with a combination of diuretic and an ARB or ACEI.

200 els estimated the causal effect of statin or ACEI/ARB initiation on neurocognitive function; initial

201 e were seen in single domains with statin or ACEI/ARB therapy, we did not find consistent evidence th

202 ohort participants not receiving a statin or ACEI/ARB within 30 days of first neurologic assessment (

203 not find consistent evidence that statins or ACEI/ARB have an effect on global neurocognitive functio

204 Among heart failure patients, ACEI use was 51% in 2002 and consistent use, 39%.

205 he exception of ARB monotherapy and ARB plus ACEI.

206 Preoperative ACEI attenuates the increase in PAI-1 after CABG, sugges

207 hrologists were not more likely to prescribe ACEI than were primary care physicians.

208 0.65-1.07; P = .15) for the group prescribed ACEIs lower than 449.5 of the cDDD and 0.43 cDDD (95% CI

209 In PTE, ACEI-related increase in erythroid progenitor apoptosis

210 iabetic patients were more likely to receive ACEI than were nondiabetic patients, but ACEI use was qu

211 nic kidney disease), 49,682 (81.7%) received ACEI/ARB with an increase in the rate of treatment over

212 ransplants analyzed, 15,250 (38.9%) received ACEI/ARB and 24,001 (61.1%) received other antihypertens

213 r death was similar in patients who received ACEI/ARB therapy or other antihypertensive treatment ove

214 Among those originally receiving ACEI therapy, however, the event rate was uniformly low

215 The cohort included 1838 patients receiving ACEI therapy before surgery and 2386 (56.5%) without ACE

216 th in kidney transplant recipients receiving ACEI/ARB or other antihypertensive medications is virtua

217 rt Association class I guideline-recommended ACEI/ARB therapy, and the use varies by patient factors.

218 patients without heart failure, 39% reported ACEI use in 2002; consistent use was 20%.

219 In normal control subjects, ACEI therapy was associated with a fall in Hct but no ch

220 continue ACEI until the morning of surgery (ACEI group, n=19) or to discontinue it 48 hours before s

221 e was associated with lower IOP and systemic ACEI, ARB, statin, and sulfonylurea use was associated w

222 ents with HF who are discharged while taking ACEIs, there is a significant decline in use after disch

223 Use of this risk model for targeting ACEI therapy was also compared with a strategy based on

224 at ARNI monotherapy is more efficacious than ACEI or ARB monotherapy.

225 Two retrospective cohort studies found that ACEI and ARB use was not associated with a higher likeli

226 nsin II at the cellular level, implying that ACEI and ARB may work by reducing intracellular calcium.

227 omized clinical investigation indicates that ACEI and a BP goal of 120/80 mmHg are associated in a 7-

228 It was shown previously that ACEI added directly to cultures of erythroid precursors

229 ated pulmonary perfusion studies showed that ACEI significantly upregulated NO production, as measure

230 High-certainty evidence suggests that ACEI or ARB use is not associated with more severe COVID

231 nts with polycythemia have demonstrated that ACEIs are effective in lowering hematocrit values.

232 The ACEI captopril and quinaprilate and the ARB candesartan

233 ogenitor apoptosis may partially explain the ACEI-associated decrease in Hct.

234 The cost-savings in the ACEI and ACEI+BB cohorts compared to that with diuretics

235 PA activity was significantly greater in the ACEI group than in the No-ACEI group (P=0.030).

236 costs and lower hospitalization rates in the ACEI+BB+AldA arm resulted in greater cost-savings.

237 In the ACEI/ARB group, 18.1% died within 30 days vs 7.3% in the

238 study tested the safety and efficacy of the ACEI ramipril on the development of CAV early after HT.

239 ejection fraction (LVEF) and similar to the ACEI in preventing heart failure with impaired LVEF.

240 m 17.0+/-5.0 to 48.7+/-8.8 ng/mL) versus the ACEI group (from 19.9+/-3.4 to 33.1+/-6.2 ng/mL).

241 The ACEIs have been shown to improve outcomes in patients wi

242 Thus, ACEIs, but not ARBs, might be effective in repairing the

243 ns of OMA alone and with diuretic (OMA+D) to ACEI+D in a model of pacing-induced congestive heart fai

244 There were 16,772 patients randomized to ACEI and 16,728 patients randomized to placebo.

245 ed for their association with BP response to ACEI in Chinese patients with hypertension in a 2-stage

246 associated with BP reduction in response to ACEI therapy in hypertensive Chinese patients.

247 The total variations in response to ACEI therapy that were explained by the AGT SNP and AGTR

248 kers to predict the hypertensive response to ACEI therapy.

249 ialysis CKD who were previously unexposed to ACEI/ARB treatment.

250 When compared with patients who did not use ACEIs, the adjusted odds ratios were 0.83 (95% CI, 0.65-

251 Among those with COVID-19, 86.5% used ACEI/ARBs vs 85.4% of controls; ACEI/ARB use compared wi

252 chance for developing ALS in people who used ACEIs greater than 449.5 cDDD in 4 years.

253 inferior RNFL quadrant in participants using ACEIs (beta = -2.44; 95% CI, -3.99 to -0.89; P = 0.002)

254 tiveness ratio (ICER) of ACEI+BB+AldA versus ACEI+BB and ACEI+BB versus ACEI was <$1,500 per quality-

255 EI+BB+AldA versus ACEI+BB and ACEI+BB versus ACEI was <$1,500 per quality-adjusted life-year.

256 This study sought to investigate whether ACEI/ARB treatment after AMI is associated with better o

257 ing graft were analyzed according to whether ACEI/ARB or other antihypertensive therapy (excluding di

258 Yet the extent to which ACEI/ARB therapy is applied in patients with acute coron

259 (adjusted HR 0.69, 95% CI 0.55-0.88), while ACEI/ARB was significantly associated with lower all-cau

260 DIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidi

261 F trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidi

262 (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidi

263 DIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidi

264 DIGM-HF (Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidi

265 DIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidi

266 F trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidi

267 ) in the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidi

268 In the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidi

269 F trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidi

270 e in the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidi

271 DIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidi

272 patients, the increase in UN associated with ACEI/ARB use could predict the development of acute resp

273 (1)) antagonism alone or in combination with ACEI are unclear.

274 point, protection has been demonstrated with ACEI only for type 1 but not type 2 diabetes.

275 categories but was significantly higher with ACEI/ARB treatment.

276 y and aldosterone immediately increased with ACEI+D, whereas OMA+D resulted in higher plasma renin ac

277 iotensin-receptor-neprilysin inhibitor) with ACEI (angiotensin-converting enzyme inhibitor) to Determ

278 iotensin Receptor-Neprilysin Inhibitor] With ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determ

279 iotensin Receptor-Neprilysin Inhibitor] with ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determ

280 iotensin Receptor-Neprilysin Inhibitor] with ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determ

281 Glomerular filtration rate was lower with ACEI+D than with either OMA group.

282 al actions comparable to those observed with ACEI+D that can be explained by potentiation of natriure

283 dosterone with OMA alone such as occurs with ACEI+D and OMA+D.

284 drenomedullin, and cGMP excretions than with ACEI+D.

285 vival was observed for patients treated with ACEI/ARB (3-year hazard ratio: 0.80; 95% confidence inte

286 Overall, those treated with ACEI/ARB also had lower 3-year risk for myocardial infar

287 Patients chronically treated with ACEI/ARB who have severe COVID-19 are at increased risk

288 in the study 30% (44/149) were treated with ACEI/ARB.

289 tal, 45,697 patients (71%) were treated with ACEI/ARB.

290 Treatment with ACEI and ACEI+BB strictly dominated treatment with diure

291 Continuous treatment with ACEI versus no ACEI was associated with substantive redu

292 ork meta-analysis showed that treatment with ACEI, ARB, BB, MRA, and ARNI and their combinations were

293 Treatment with ACEI/ARB after AMI was associated with improved long-ter

294 ssion analysis confirmed that treatment with ACEI/ARB did not confer a beneficial effect beyond that

295 However, treatment of COVID-19 with ACEIs/ARBs poses several challenges.

296 Patients not discharged with ACEIs are unlikely to be started as outpatients.

297 F/total cohort) of survivors discharged with ACEIs had filled a prescription by 30 days postdischarge

298 55% of the total cohort were discharged with ACEIs.

299 Assuring therapy with ACEIs at discharge after HF hospitalization is a key Med

300 rapy before surgery and 2386 (56.5%) without ACEI exposure.